The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...

Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...

The athletic apparel company said Chief Executive Officer Calvin McDonald will step down in January and relinquish his board ...

Millions of Americans have successfully lost weight with semaglutides, the game-changing class of drugs that includes Ozempic ...

A committee inside of Europe's top drug regulator on Friday recommended extending the use of Eli Lilly'sLLY blockbuster type ...

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

Novo Nordisk has launched its blockbuster diabetes drug Ozempic in India, pricing the starter dose at ₹8,800 per month (₹2,200 per week), positioning it as a competitor to Eli Lilly's Mounjaro (priced ...

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

The Delhi High Court ruled against Novo Nordisk's request to block Dr Reddy's production of semaglutide for export. The case ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...